| | By Fraiser Kansteiner Pfizer is cutting roughly 200 positions at its Kalamazoo site following a review of demand for its COVID-19 vaccine and antiviral Comirnaty and Paxlovid. |
|
|
|
By Kevin Dunleavy In three years as the pharma chief at Roche, Bill Anderson executed a massive overhaul of the division, lopping off layers of management and recharting its course. Now in his fifth month as CEO at struggling conglomerate Bayer, Anderson is focused on an even larger renovation, saying the company is on its way to a “radical realignment” with massive reductions in its workforce. As part of the realignment, Bayer also is evaluating separating its consumer health and crop science divisions. |
By Andrea Park Changes are afoot within Siemens Healthineers’ diagnostics business—though it’s still unclear just how far those changes will go. |
By James Waldron More than a decade after AstraZeneca appeared to give up hope of using zibotentan to treat prostate cancer, the endothelin receptor antagonist has received a new lease on life as a combo treatment for chronic kidney disease. |
By Annalee Armstrong Another day, another antibody-drug conjugate deal. This time it’s Bristol Myers Squibb snapping up Orum Therapeutics’ phase 1 blood cancer med for $100 million upfront. |
By Kevin Dunleavy In the Big Pharma battle to treat obesity, Novo Nordisk sprinted to an early lead, but Eli Lilly is catching up quickly. Wednesday's FDA approval of Lilly's Zepbound to treat obesity closes the gap further. In addition, Lilly said it will charge 20% less than Novo for its obesity med in an attempt to provide increased access. |
By Helen Floersh Academics and industry folks from around the cancer world convened in sunny San Diego Nov. 1-5 at the Society for Immunotherapy of Cancer’s annual conference. Here are a few preclinical highlights. |
By Max Bayer Pfizer has handed off an AAV capsid aimed at a rare neurological disease target to AstraZeneca’s rare disease arm Alexion as part of a larger, previously announced bundle deal. |
By Joseph Keenan India’s Natco Pharma was hit with a Form 483 by the FDA following an inspection that resulted in eight observations. The citation centered on a lack of cleanliness and sterility of equipment plus problems with the site’s quality control systems. |
By Ben Adams It’s all the rage for superhero films: Bring together several fan favorite celebrities into one cinematic event. Pfizer is following Marvel and DC’s lead, bringing together its five most recent COVID commercial celebrities for a new ad promoting its booster. |
Fierce podcastsDon’t miss an episode |
| | Hello Heart is a U.S.-based company with offices in California and New York, and it also has a significant presence in Israel, with the majority of its roughly 80 employees there working from the Tel Aviv office. In this week’s episode of “Podnosis,” Hello Heart CEO Maayan Cohen, who resides in Tel Aviv, shares her personal experience during a challenging moment when she was on her way to the annual HLTH conference in Las Vegas and heard about the October 7th attack by Hamas on Israel. |
|
|---|
|
|
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperIs pharma spending money on the wrong types of AI? Here’s how real-time clinical alerts could change the minds of the world’s top commercial leaders. Sponsored by: Viz.Ai |
| WhitepaperWant to know the Top 5 criteria for selecting the ‘right’ CDMO for pDNA manufacturing? Sponsored by: Syngene |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperLearn more about targeted personas for HCP marketing. Sponsored by: M3 |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
